What are the recent trends in market size and growth for the locally advanced pancreatic cancer market?
The locally advanced pancreatic cancer market size has grown rapidly in recent years. It will grow from $0.95 billion in 2024 to $1.05 billion in 2025 at a compound annual growth rate (CAGR) of 10.9%. The growth in the historic period can be attributed to increase in awareness of pancreatic cancer, improved chemotherapy regimens, growth in use of targeted therapies, rise in incidence of pancreatic cancer, development of combination treatment protocols, and enhanced supportive care options.
The locally advanced pancreatic cancer market size is expected to see rapid growth in the next few years. It will grow to $1.57 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increase in awareness of pancreatic cancer, improved chemotherapy regimens, growth in use of targeted therapies, rise in incidence of pancreatic cancer, development of combination treatment protocols, and enhanced supportive care options. Major trends in the forecast period include advancements in immunotherapy, development of targeted therapies, enhanced precision radiation techniques, improved diagnostic imaging, adoption of minimally invasive surgical approaches, integration of artificial intelligence in treatment planning, and advancements in combination therapy.
Get Your Free Sample of The Global Locally Advanced Pancreatic Cancer Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp
How have varous drivers impacted the growth of the locally advanced pancreatic cancer market?
The increase in tobacco consumption is expected to drive the growth of the locally advanced pancreatic cancer markets going forward. Tobacco is a plant whose leaves are used in products such as cigarettes and cigars. It contains nicotine, which is addictive and is linked to serious health issues such as cancer and heart disease. The rising tobacco consumption is driven by factors such as easy access, affordability, tobacco marketing, social acceptance in some areas, and stress-related smoking. Tobacco consumption is a significant risk factor for the development of locally advanced pancreatic cancer, as it contributes to the increased incidence of pancreatic malignancies. For instance, in January 2024, according to the Global Action to End Smoking, a US-based non-profit organization for research related to end the smoking epidemic, in 2022, around 62.9 million adults in the U.S. used tobacco, ranking it 4th globally and 1st in the Americas. Further, around 11.5% of U.S. adults (28.3 million) smoked cigarettes, with higher rates among males (13.1%) than females (10.1%). Therefore, the increase in tobacco consumption is driving the growth of the locally advanced pancreatic cancer market.
What are the primary segments of the locally advanced pancreatic cancer market?
The locally advanced pancreatic cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Surgery
2) By Route Of Administration: Oral, Injectables, Other Route Of Administrations
3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users
Subsegments:
1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy
2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines
3) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)
4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure), Distal Pancreatectomy, Total Pancreatectomy
Order your report now for swift delivery
Which firms are leading the locally advanced pancreatic cancer market?
Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co
How will industry trends affect the trajectory of the locally advanced pancreatic cancer market?
Major companies operating in the locally advanced pancreatic cancer market are focusing on developing innovative products, such as orphan drugs, to enhance treatment options, improve patient outcomes, and address the unmet medical needs associated with this aggressive disease. Orphan drugs are designed to treat rare diseases affecting a small group of people and are incentivized by authorities with benefits such as tax reductions and market exclusivity to promote their development. For instance, in January 2025, Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its Elraglusib, a new GSK-3ß inhibitor, has received Orphan Drug Designation from both the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for treating pancreatic ductal adenocarcinoma (PDAC) (a potential types of locally advanced pancreatic cancer). This recognition highlights its potential to fill a critical gap in treating this severe cancer, especially after promising Phase 2 trial results showing significant clinical improvements and anti-tumor effects in metastatic PDAC patients.
Which geographic trends are shaping the locally advanced pancreatic cancer market, and which region has the highest market share?
North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Locally Advanced Pancreatic Cancer Market Report 2025 Offer?
The locally advanced pancreatic cancer market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Locally advanced pancreatic cancer (LAPC) refers to a stage of pancreatic cancer where the tumor is confined to the pancreas and surrounding tissues but has not spread to distant organs. This cancer is usually not suitable for surgical removal due to its involvement with vital blood vessels or nearby structures.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21214
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
